Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 7Dyspepsia 3Peptic Ulcer 2Gastritis 2Pseudomyxoma Peritonei 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Familial primary gastric lymphoma 1Drug-Related Side Effects and Adverse Reactions 1Atrophy 1Appendiceal Neoplasms 1

Interventions

Oxaliplatin 11Mitomycin 11Leucovorin 7Hyperthermic Intraperitoneal Chemotherapy 7Irinotecan 6Fluorouracil 6Cisplatin 4Capecitabine 4Surveys and Questionnaires 3Doxorubicin 3Cytoreduction Surgical Procedures 3dehydroftorafur 2Trastuzumab 2Thalidomide 2Mitozytrex 2Melphalan 2Interleukin-12 Subunit p35 2Floxuridine 2Drug Therapy 2Cetuximab 2Biopsy 2tipifarnib 1surufatinib 1sodium thiosulfate 1sintilimab 1nintedanib 1nilotinib 1motexafin lutetium 1irinotecan sucrosofate 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Appendiceal Neoplasms × Clarithromycin × Gastrointestinal × Clear all
NCT02387203 2024-11-19

Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin

Mercy Medical Center

Phase 2 Active not recruiting
80 enrolled
Gastrointestinal

Appendiceal Neoplasms, Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon âš¡